Imatinib for secondary Ph+ acute lymphoblastic leukemia induces response in concomitant GBM

Ann Oncol. 2006 Apr;17(4):720-1. doi: 10.1093/annonc/mdj056. Epub 2005 Nov 1.

Authors

S De Vita, S De Matteis, L Laurenti, P Chiusolo, F Sorà, N Piccirillo, G Reddiconto, A Fiorini, G Leone, S Sica

PMID: 16263757
DOI: 10.1093/annonc/mdj056

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Adult
Antineoplastic Agents / therapeutic use*
Benzamides
Brain Neoplasms / drug therapy*
Glioblastoma / drug therapy*
Humans
Imatinib Mesylate
Male
Neoplasms, Second Primary / drug therapy*
Neoplasms, Second Primary / genetics
Philadelphia Chromosome*
Piperazines / therapeutic use*
Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy*
Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics
Pyrimidines / therapeutic use*

Substances

Antineoplastic Agents
Benzamides
Piperazines
Pyrimidines
Imatinib Mesylate